NLS Days, September 8-9, 2026, Stockholm, Sweden.

Nordic Life Science Days is the largest life science partnering event in the Nordics. NLS Days gathers big pharma executives, investors and CEOs of biotech, pharma and medtech companies and discusses the road ahead for the life science industry.

Please do not hesitate to book a meeting, either during the conference or at a time convenient for you, to discuss how you can benefit from our valuation and consulting services.

(May 2026)

IPLS, September 14-16, 2026, Stockholm, Sweden.

Join business development leaders from across Europe in Stockholm for the 20th anniversary of IPLS, the international partnering event bringing together members from national IPLS groups to spark ideas, deals, and lasting relationships.

Please do not hesitate to book a meeting, either during the conference or at a time convenient for you, to discuss how you can benefit from our valuation and consulting services.

(May 2026)

LSX World Congress, September 23-24, 2026, Boston, USA.

LSX Congress USA is where biotech companies at different stages of growth come to meet the investors and pharma partners who can help shape what comes next. From emerging biotechs seeking capital and visibility to later-stage companies pursuing strategic partnerships and commercial momentum, the event is built around the conversations that matter most.

Please contact us to book a meeting, either during the conference or at a time convenient for you, to discuss how you can benefit from our valuation services.

(May 2026)

Bio-Europe, November 9-11, 2026, Cologne, Germany.

BIO-Europe 2026 is Europe's largest annual life science partnering conference, taking place in Cologne, Germany, from November 9–11. It attracts thousands of executives from global biotech, pharma, and finance to drive strategic licensing, investment, and collaboration across the industry.

Please contact us to book a meeting, either during the conference or at a time convenient for you, to discuss how you can benefit from our valuation services.

(May 2026)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

(October 2024)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

(June 2018)